Structure / Market Size The US Sector $ 12 billion valued pharmaceutical industry in India is expected to grow at an compound annual growth rate (CAGR) of 10-11 per cent. The industry spends around 18 per cent of its revenue on research and development (R&D).
Thousands of Americans claim that African mango works on losing your weight. An exotic skinny fruit, African mango is day by day becoming the hottest diet for Americans. An African Mango Diet has been called a “wonder weight loss drug”, and many have shared testimonials of the weight loss benefits.
Malaria has been a serious issue since a long period of time and controlling malaria has been a top goal of international public-health authorities. Caused by parasites transmitted by infected mosquitoes, malaria annually sickens more than 200 million people and kills nearly 800,000, mostly children in Africa. Because children are the most vulnerable to the disease, efforts to develop a vaccine have focused on them.
The Indian drug industry could make huge gains as over $70 billion worth of drugs are expected to go off patent in the US, the world’s largest pharma market, in the next three years.
Scientists may have finally found a way to deal with one of developing world's worst problems in healthcare — faulty and inadequate cold chain for vaccine storage. British scientists from Oxford University have found a way to keep vaccines stable even in room temperature.
In this arena, we believe there should be two broad priorities for India. First, to ensure that there is timely access to affordable quality medicine for the underprivileged. Second, due to the global scale and impact of the Indian pharmaceutical industry, to ensure that we give it the most comprehensive support that it deserves.
Like pharma giants Pfizer, Eli Lilly and Merck & Co, US biotechnology major Biogen Idec also doesn’t want to miss the India opportunity.
Surging growth and global operations ensure they can’t be family-run any longer.
Avesthagen’s systems biology approach to novel products targets more than land based organisms – dives deep into new products from the OceanAvesthagen has always been in the forefront of innovative scientific thinking and has developed a formidable portfolio of patents in all the four areas it operates in viz. bioAgriculture, bioNutrition, bioPharmacueticals and in Science & Innovation. Approximately 600 patent applications cover both, process and products. There are several copyrights and design patents as well. Within each area Avesthagen aspires to benefit the common man, and more so for the “bottom of the pyramid”.
India might be shining for multinational drugmakers, but when it actually comes to introducing innovator drugs the $20 billion Indian pharma market is light years away.
In a first-ever initiative to bring down prices of expensive cancer medication, the government plans to retail them through its ‘Jan Aushadhi’ stores, which offer essential ‘unbranded’ drugs at discounted rates. It has already initiated talks with domestic pharma companies to procure cancer drugs.
Delhi High Court dismisses six petitions of drug majors.
Troikaa Pharmaceuticals, a Gujarat based fast growing healthcare company, is likely to get US patent for its novel drug delivery form of Diclofenac injections-Dyanapar AQ.
The collapse of the property market has left the economy with a huge hole that will be difficult to fill. One of the few sectors that offers hope of growth is the pharmaceutical industry, with senior executives convinced that genuine opportunities remain for Ireland Inc.
A global study by Health Action International, a non-government body, on the price variations of Ciproflaxin, a commonly used medicine in 93 countries, found the price charged by Bayer, the originator of the drug, to be the lowest in India.
Union Health and Family Welfare Minister Ghulam Nabi Azad and Gujarat Chief Minister Narendra Modi, on Saturday invited expatriates to invest in the country.
Domestic drug companies, who have been challenging drug patents in the US and Europe, are now taking the first steps to challenge patents granted in India to companies based there.
Citing people familiar with the matter, pharmaquest.biz reported that Glaxo will take a 20-per cent stake in Dr. Reddy's Holdings Ltd., a family vehicle that owns 23.2 per cent of the Hyderabad-based Dr Reddy's Laboratories.
In one stroke, Swiss pharma giant Novartis AG could break into the league of top five players in the Rs 600-crore plus Indian eyecare market from its current position at 13, if its takeover of Alcon goes through seamlessly and eventually results in integration of Alcon India into the Indian arm of Novartis. Such a combined entity of Novartis and Alcon would then command a marketshare of 7.5% in the domestic eyecare market, just 1.4% less compared with the third and fourth ranked companies, FDC and Sun Pharma, which command 8.9% marketshare each.
The domestic pharmaceutical industry has urged the government to withdraw a study launched by the World Health Organization (WHO) in consultation with the Union ministry of health on implementing 'Data Exclusivity' in India.